ETF Components for ARKG - ARK Genomic Revolution Multi-Sector ETF


Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

Holdings

Symbol Grade Price % Change Allocation
TWST D 1.37 8.37
RXRX F -0.87 7.42
CRSP D 3.43 7.34
ADPT C 7.32 5.03
CDNA D 2.44 4.77
VCYT B 1.67 4.51
SDGR C 2.31 4.14
BEAM D 6.23 4.01
NTLA F 3.62 3.89
IONS F 0.21 3.85
NTRA B -1.24 3.82
NRIX D -1.43 3.78
TXG F 7.67 3.56
GH B 5.39 3.49
ARCT F -0.94 3.19
PSNL D 2.66 2.70
ABSI F 0.39 2.19
PACB F 1.69 2.16
BFLY B -1.52 1.71
VEEV C 0.95 1.70
AMGN D 1.60 1.68
ACCD D -0.27 1.47
VRTX F 0.13 1.29
ILMN D 2.30 1.25
CERS C 7.19 1.18
INCY C 1.89 1.11
REGN F -0.87 0.92
PRME F 7.74 0.90
CMPS F -0.90 0.75
MASS F -6.57 0.69
QSI C 33.88 0.68
EXAS D -0.30 0.65
RPTX F -5.39 0.64
MRNA F 7.48 0.01

Recent News for ARK Genomic Revolution Multi-Sector ETF & its Holdings

Date Stock Title
Nov 23 INCY What Moved Markets This Week
Nov 22 MRNA Jefferies says market nears short term “peak RFK negativity", Vaccine makers up
Nov 22 GH Guardant Health (GH) Set To Dominate The Growing Liquid Biopsy Market
Nov 22 MRNA Goldman Sachs: Moderna, Inc. (NASDAQ:MRNA) Is A Top Growth Investor Stock
Nov 22 MRNA Moderna Stock Jumps Following Bullish Sales View at Healthcare Conference
Nov 22 MRNA Moderna up 8% as Jefferies says market is close to 'peak RFK negativity'
Nov 22 MRNA Moderna's Fresh Blow As RFK Heads To HHS - A Tough 2025 May Be In Store
Nov 22 RXRX 2 Innovative Stocks That Could Deliver Outsize Returns
Nov 22 BFLY Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?
Nov 22 AMGN Why Amgen (AMGN) is a Top Value Stock for the Long-Term
Nov 22 NTLA Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock?
Nov 22 AMGN RFK Jr. Spooks Weight-Loss Stocks. Should Eli Lilly, Novo Nordisk Be Worried?
Nov 22 VRTX Goldman Sachs: Vertex Pharmaceuticals Incorporated (VRTX) Is A Top Growth Investor Stock
Nov 22 INCY Goldman Sachs: Incyte Corporation (INCY) Is A Top Growth Investor Stock
Nov 22 VRTX Got $500? 1 Biotech Stock to Buy and Hold Forever
Nov 21 MRNA Why Is Moderna, Inc. (MRNA) Among the Worst Performing Biotech Stocks in 2024?
Nov 21 NTRA Natera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM
Nov 21 IONS Why Is Ionis Pharmaceuticals, Inc. (IONS) Among the Worst Performing Biotech Stocks in 2024?
Nov 21 CRSP Why Is CRISPR Therapeutics AG (CRSP) Among the Worst Performing Biotech Stocks in 2024?
Nov 21 VEEV Elastic (ESTC) Tops Q2 Earnings and Revenue Estimates
Companies within ARKG are focused on and are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments and advancements in genomics into their business. The companies held in ARKG may develop, produce or enable: CRISPR Targeted Therapeutics Bioinformatics Molecular Diagnostics Stem Cells Agricultural Biology ARKG will be concentrated in issuers in any industry or group of industries in the health care sector, including issuers having their principal business activities in the biotechnology industry. ARKG is an actively managed ETF that seeks long-term growth of capital by investing under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including health care, information technology, materials, energy and consumer discretionary, that are relevant to the Fund’s investment theme of the genomics revolution.
Exchange Traded Fund ETF Biotechnology Stem Cell Genomics Bioinformatics
Back to the Main ARKG Page...